Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Third-Line Gastric Cancer: TROP2-Directed Sac-TMT Met Its Overall Survival Goal in the TroFuse-015 Trial

Third-Line Gastric Cancer: TROP2-Directed Sac-TMT Met Its Overall Survival Goal in the TroFuse-015 Trial
In this article

A TROP2-Directed ADC in Previously Treated Gastric Cancer: What TroFuse-015 Showed, and What It Has Not Yet Shown

According to a press release Merck issued on November 20, 2026, the TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) improved overall survival, with statistical significance and clinical value, compared with physician's-choice chemotherapy in 473 patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who had received at least two prior lines of treatment. That was the primary goal of the randomized, open-label phase 3 TroFuse-015 trial. However, the secondary goal of progression-free survival by blinded independent central review was not met, and median survival and the hazard ratio (HR) have not yet been reported. This is not an approval; it is an initial results announcement. It is an important development at a stage with very few options, but without the size of the difference it is too early to say how important. I covered the stages and treatment of gastric cancer in this article, the TROP2 target in my TROP2 article, and sac-TMT's results in breast cancer in this article (all in Turkish).

473patients; randomized, open-label phase 3 TroFuse-015
≥2prior lines of treatment; third line and beyond
✓ / ✗overall survival goal met; progression-free survival goal not met
?median survival and hazard ratio not yet reported
Quick Answer · Physician Summary
  • What was studied? 473 patients with gastric/GEJ adenocarcinoma that had progressed after at least two lines, regardless of HER2 and TROP2 status, were randomized 1:1 to sac-TMT (4 mg/kg; days 1, 15 and 29 of a 6-week cycle) or physician's-choice chemotherapy (trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel).
  • Result: The primary goal, overall survival, was met. The secondary goal, progression-free survival by independent review, was not met. The response rate numerically favored sac-TMT, but no formal statistical test was done. No new safety signal was reported.
  • Unknown: Median overall survival, HR and confidence intervals, side-effect rates and TROP2 subgroups. Without them, the clinical size of the difference cannot be interpreted.
  • In practice: Sac-TMT is not approved in any country outside China and is not licensed in Turkey. At this stage today's options are trifluridine-tipiracil, trastuzumab deruxtecan in HER2-positive disease, and clinical trials.

Why does this matter?

Gastric cancer is the fifth most common cancer worldwide and among the leading causes of cancer-related loss of life; in Turkey it is also common, and most patients are diagnosed at an advanced stage (intestinal metaplasia and gastric cancer risk, in Turkish). First-line treatment for advanced disease has improved clearly in recent years: immunotherapy is added to chemotherapy, trastuzumab in HER2-positive disease, and zolbetuximab in claudin 18.2-positive disease (the best starting chemotherapy, zolbetuximab, immunotherapy in gastric cancer; all in Turkish). In the second line, ramucirumab with paclitaxel is used, and trastuzumab deruxtecan in HER2-positive disease (Enhertu or ramucirumab-paclitaxel?, in Turkish).

In the third line and beyond, the picture is still hard. The share of patients who reach this stage is low, and most of those who do have a declined general condition. In phase 3 trials, median overall survival at this stage stays around 4-6 months. In the TAGS trial, trifluridine-tipiracil (Lonsurf) extended median survival from 3.6 to 5.7 months compared with placebo (Lonsurf approval, in Turkish). The importance of TroFuse-015 is that it shows a survival advantage against active chemotherapy, not placebo.

Phase 3 data in the third line to date: median overall survival

Advanced gastric / GEJ cancer after at least two prior lines; months.

Trifluridine-tipiracil (TAGS)
5.7 months
Nivolumab (ATTRACTION-2, Asia)
5.3 months
Placebo (TAGS control arm)
3.6 months
Trastuzumab deruxtecan, HER2-positive only (DESTINY-Gastric01, phase 2)
12.5 months

Median survival has not yet been reported for sac-TMT; in TroFuse-015 the control arm is active chemotherapy, not placebo. DESTINY-Gastric01 is a randomized phase 2 trial that included only HER2-positive patients. Comparisons across different trials are indirect; patient groups, prior treatments and follow-up times differ.

Figure 1 · Treatment lines in advanced gastric/GEJ cancer

Which line does TroFuse-015 target?

1st linefluoropyrimidine + platinum; by biomarkerimmunotherapy, trastuzumab or zolbetuximab2nd lineramucirumab + paclitaxel;in HER2-positive, trastuzumab deruxtecan3rd line and beyondtrifluridine-tipiracil; nivolumab in Asia;most patients never reach this lineTroFuse-015 in this lineTROP2-directed ADC sac-TMT versus physician'schoice chemotherapy: survival improved
How to read it: In the first line, immunotherapy, trastuzumab or zolbetuximab is added to fluoropyrimidine and platinum chemotherapy according to biomarkers. In the second line, ramucirumab with paclitaxel is used, and trastuzumab deruxtecan in HER2-positive patients. In the third line and beyond, trifluridine-tipiracil and, in Asia, nivolumab are among the options; however, a large share of patients do not reach this line. In this last line, TroFuse-015 compared the TROP2-directed ADC sac-TMT with physician's-choice chemotherapy and improved overall survival.
Is It a First?
  • Yes (per the company): The first TROP2-directed ADC to improve overall survival in a global phase 3 trial at this stage.
  • No: It is not the first drug to extend survival in third-line gastric cancer; trifluridine-tipiracil and, in Asian patients, nivolumab showed a survival advantage in phase 3 earlier. Nor is it the first effective ADC in gastric cancer; trastuzumab deruxtecan is approved in HER2-positive patients.
  • Not yet: There is no approval or filing for sac-TMT in gastric cancer in any country; the data will be presented at a congress and shared with authorities. The first FDA filing is under priority review for endometrial cancer.
2017
ATTRACTION-2
Nivolumab extended survival in the third line in Asian patients.
2018-2019
TAGS and Lonsurf approval
Trifluridine-tipiracil, median survival 5.7 versus 3.6 months with placebo.
2020-2021
DESTINY-Gastric01
Trastuzumab deruxtecan in HER2-positive patients; the ADC era in gastric cancer began.
November 2024
First approval (China)
Sac-TMT was approved in China in triple-negative breast cancer.
November 20, 2026
TroFuse-015
Third line and beyond in gastric/GEJ cancer: overall survival goal met.

What Is Sacituzumab Tirumotecan (Sac-TMT)?

Sacituzumab tirumotecan (sac-TMT, MK-2870) is an antibody-drug conjugate in which a topoisomerase-I inhibitor chemotherapy payload is attached to an antibody that binds the TROP2 protein on the surface of tumor cells. It is approved in China in breast and lung cancer; in gastric cancer it is not yet approved in any country; Merck is studying it in 18 global phase 3 trials across different cancers.

TROP2 is a surface protein present at high levels in many tumors of epithelial origin, including gastric cancer. Sac-TMT was developed by China's Kelun-Biotech; Merck (MSD outside the US and Canada) holds the rights outside China. The drug was approved in China in November 2024 in triple-negative breast cancer, then in EGFR-mutant lung cancer. Merck has 18 global phase 3 trials with sac-TMT under way. From the same class, sacituzumab govitecan and datopotamab deruxtecan are used in breast and lung cancer (datopotamab or sacituzumab?, what is an ADC?; both in Turkish).

What Was Done in the TroFuse-015 Trial?

TroFuse-015 (NCT06356311) is a global, multicenter, randomized, open-label phase 3 trial. It enrolled 473 patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma whose disease had progressed after at least two lines of treatment and who were in good general condition (ECOG 0-1). Patients were accepted regardless of HER2 status; HER2-positive patients had to have received trastuzumab before. Patients who had previously received a TROP2-directed ADC or an ADC with a topoisomerase-I payload were excluded.

TROP2 positivity was not required for entry; however, tumor tissue from all patients was assessed for TROP2 in a central laboratory, and randomization was balanced by TROP2 level, geographic region and general condition. The company reports that results were consistent regardless of TROP2 level. This matters because, if true, a separate TROP2 test may not be needed before treatment.

Figure 2 · Design of the TroFuse-015 trial

Phase 3, randomized (1:1), open-label

473 patients · phase 3 · open-label · 1:1gastric / GEJ adenocarcinoma after at least 2 linesregardless of HER2 and TROP2 status Sac-TMT4 mg/kg intravenously;days 1, 15 and 29of a 6-week cyclePhysician's choicetrifluridine-tipiracil,irinotecan, paclitaxelor docetaxel Primary endpoint: overall survivalsecondary: PFS (BICR), response, safety
How to read it: 473 patients with gastric or gastroesophageal junction adenocarcinoma that had progressed after at least two lines, regardless of HER2 and TROP2 status, were randomly split into two equal groups. One group received intravenous sac-TMT 4 mg/kg on days 1, 15 and 29 of a 6-week cycle. The other group received physician's-choice chemotherapy: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. The primary endpoint was overall survival; progression-free survival by independent review, response rate, duration of response and safety were secondary endpoints.

How Should the Results Be Read?

The press release tells us three things: the overall survival difference is statistically significant; the progression-free survival difference is not significant on independent review; and no new safety problem was seen. These are promising, but most of the information needed for interpretation is missing.

First, the size of the difference is unknown. At this stage median survival is already around 5-6 months. An HR between 0.70 and 0.85 could mean a difference of a few weeks or of 2-3 months in median survival. When life is short, a few months are valuable too; but that difference has to be weighed together with side effects and quality of life.

Second, it is not unusual for overall survival to lengthen without a significant gain in progression-free survival. There may be several explanations: progression-free survival is already very short at this stage, and a difference may be missed because of imaging timing between the two arms; the effect of sac-TMT may take the form of slower progression of disease rather than tumor shrinkage; and because the trial is open-label, there may be differences between local and independent assessment. Overall survival is the result least affected by such biases and the most meaningful for the patient; so in my view meeting the primary goal is more decisive. Still, the absence of a difference in progression-free survival should be read as a warning that the effect may not be large.

Figure 3 · What Is and Is Not in the Press Release?

Where the TroFuse-015 results stand today

Overall survivalprimary goalmet PFS (BICR)secondary goalnot met Response ratefavors sac-TMT;not formally tested Median and HRnot yetreported Safetyno new signal;details awaited Approvalnone; data will besubmitted to authorities
How to read it: The primary goal, overall survival, was met. The secondary goal, progression-free survival by independent review, was not met. The response rate numerically favored sac-TMT but, by the analysis plan, was not formally tested. Median survival and the hazard ratio have not yet been reported. The safety profile is consistent with earlier sac-TMT studies; no new signal was reported, and details are awaited. This is not an approval; the data will be presented at a congress and shared with authorities.

Third, the control arm is strong. Physician's-choice chemotherapy covers trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. This is a tougher comparison than older trials against placebo. However, it is not known in what proportion patients received which chemotherapy, or whether patients who had received ramucirumab-paclitaxel in the second line were given a taxane again; these details affect the strength of the control arm.

What Are the Side Effects?

Merck states that the safety profile is consistent with earlier sac-TMT studies and that no new signal was seen; however, no numerical data were shared. In earlier studies the most common side effects of sac-TMT were drops in blood counts (especially neutrophils and hemoglobin), mouth sores (stomatitis), nausea, hair loss and rash. Stomatitis is managed with mouth care and, when needed, steroid mouth rinses. Although the risk of lung inflammation (interstitial lung disease) seen with topoisomerase-I-payload ADCs has been reported as low for sac-TMT, it needs close monitoring. Managing these side effects is especially important in third-line patients whose general condition is borderline.

The Situation in Turkey and What It Means in Practice for Patients

Sac-TMT is not licensed in Turkey; in gastric cancer it is not yet approved in any country. For this reason, importing the drug from abroad is not possible today either. Full disclosure of the TroFuse-015 results and then review by regulators will take time.

My advice today for my gastric cancer patients who have already had two lines of treatment is this: if general condition is good, consider proven options such as trifluridine-tipiracil; revisit HER2 status (if HER2-positive, trastuzumab deruxtecan is an important option); and ask whether a suitable clinical trial exists (what is a clinical trial?, why does clinical research matter?; both in Turkish). In patients who have not had immunotherapy, immunotherapy options by MSI and PD-L1 status should also be discussed (nivolumab, the first immunotherapy approval in gastric cancer, tislelizumab; all in Turkish). Supportive care, nutrition and pain control are an inseparable part of treatment at every line.

Research on new targets in gastric cancer is moving quickly: claudin 18.2, FGFR2b, DKK1 and TROP2 are among the leaders (the claudin-directed zolbetuximab approval, Vyloy, DKN-01 and tislelizumab; all in Turkish). For the place of immunotherapy in esophageal and junction cancers, you can also see my articles on the pembrolizumab approval and the development of immunotherapy (in Turkish).

Questions You Can Ask Your Doctor

  • What are the HER2, PD-L1, MSI and claudin 18.2 statuses of my tumor, and how do they affect my next treatment?
  • What proven options are there for me in the third line, and what benefits and side effects can be expected?
  • Is there a clinical trial I might be eligible for?
  • When might new drugs such as sac-TMT become available in Turkey?
  • What supportive treatments can I use for nutrition, pain and fatigue?
Common Misconceptions
  • "The trial was positive, so the drug can be used now." No. This is a press release; the drug is not approved in gastric cancer in any country and is not licensed in Turkey.
  • "If the survival goal was met, the difference is big." No. Statistical significance does not show the size of the difference; without median survival and HR it cannot be known.
  • "If progression-free survival is not significant, the drug does not work." No. Improvement in the primary goal, overall survival, is the most important result; progression-free survival can be short and hard to measure at this stage.
  • "I need to get a TROP2 test." Not for now. TROP2 positivity was not required in the trial, and results were reported to be consistent regardless of TROP2 level.
  • "There is no point in treatment in the third line." No. In patients with a suitable general condition there are treatments that extend life at this stage too; the decision should weigh benefit and burden together.

Frequently Asked Questions

What is the TroFuse-015 trial?
It is a randomized, open-label phase 3 trial in 473 patients with advanced gastric and gastroesophageal junction adenocarcinoma and at least two prior lines of treatment, comparing the TROP2-directed ADC sacituzumab tirumotecan with physician's-choice chemotherapy.
What result did sac-TMT give in gastric cancer?
It significantly improved the primary goal, overall survival, compared with chemotherapy; no significant difference was found in progression-free survival by independent review. Median survival and the hazard ratio have not yet been reported.
Is sac-TMT available in Turkey?
No. Sac-TMT is approved only in China, in breast and lung cancer; in gastric cancer it is not approved in any country and is not licensed in Turkey.
What treatments exist today for third-line gastric cancer?
Trifluridine-tipiracil, trastuzumab deruxtecan in HER2-positive patients, nivolumab in Asia, and clinical trials in suitable patients. The choice is made according to prior treatments, biomarkers and general condition.

Glossary

Gastroesophageal junction (GEJ)
The area where the esophagus joins the stomach; tumors here are treated like gastric cancer.
Adenocarcinoma
A type of cancer that develops from secretory gland cells; the large majority of gastric cancers.
TROP2
A surface protein present at high levels in many solid tumors; a target for ADCs.
Antibody-drug conjugate (ADC)
A drug made by attaching a chemotherapy payload to an antibody that recognizes the tumor.
Topoisomerase-I inhibitor
A type of chemotherapy that blocks the cell's DNA replication; the payload of sac-TMT.
Physician's-choice treatment
The standard treatment the physician selects in the control arm from predefined options.
Overall survival
The length of time patients live after treatment begins; the most important endpoint.
Progression-free survival
The length of time disease does not progress.
BICR
Blinded independent central review; images are assessed by experts who do not know the treatment.
Hazard ratio (HR)
The relative difference in event risk between two groups; below 1 favors the experimental treatment.

DROZDOGAN Academy Commentary

Showing a survival advantage against active chemotherapy in previously treated gastric cancer is not easy. TroFuse-015 achieved this; but without yet knowing the size of the difference, it is impossible to say what this success gives the patient.

⚡ Why it matters

No new survival advantage had been seen in the third line for years. A TROP2-directed ADC working in gastric cancer too suggests that ADCs can reach patients beyond HER2 and be used in a broad patient group without a TROP2 test.

✅ Strengths

Randomized phase 3 design; an active and realistic control arm; overall survival, the most meaningful result for the patient, as the primary goal; a broad patient group regardless of HER2 and TROP2 status; global participation.

⚠️ Limits

Only a press release is available; median survival, HR, confidence intervals, side-effect rates and quality of life are unknown. The absence of a difference in progression-free survival suggests the effect may be limited. The open-label design and the distribution of chemotherapy in the control arm may affect results; whether there is a difference between Asian and Western patients is also an important question.

🩺 In practice

Nothing changes in my practice today. In my third-line patients I weigh general condition, prior treatments and biomarkers together, recommend proven options such as trifluridine-tipiracil or, in HER2-positive patients, trastuzumab deruxtecan, and look for suitable clinical trials. When the full results are released, I will reassess according to the size of the difference and the side-effect burden.

❓ Open questions

How many months is the difference in median survival? Is quality of life preserved? Is the benefit truly similar in tumors with high and low TROP2? Could sac-TMT be more effective in earlier lines or together with immunotherapy? When and under what conditions will access be possible in Turkey?

Conclusion: An important and positive signal; but for the full picture we need to wait for the congress presentation and publication. The size of the difference will decide whether this result "adds an option" or "changes the standard."

Transparency Note
  • This article was prepared in November 2026.
  • The TroFuse-015 information comes from professional news sources relaying Merck's press release of November 20, 2026; the full text of the press release and the numerical results of the trial were not accessible when this article was prepared. There is no peer-reviewed publication or congress presentation yet.
  • Comparisons in the chart are indirect; patient groups, time periods and control arms differ between studies.
  • The diagrams are simplified. The Academy commentary is my own. This article is not medical advice; make your treatment decisions together with your doctor.

Sources

  1. Merck. Merck announces TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT) met primary endpoint of overall survival. Press release, 20 November 2026. stockhouse.com
  2. TroFuse-015 meets primary OS end point with sac-TMT in third-line or later gastroesophageal adenocarcinoma. OncLive, 20 November 2026. onclive.com
  3. Sac-TMT meets OS end point in pretreated gastroesophageal adenocarcinoma. CancerNetwork, 20 November 2026. cancernetwork.com
  4. TroFuse-015. ClinicalTrials.gov NCT06356311. clinicaltrials.gov
  5. Kelun-Biotech. Sac-TMT approved by NMPA for EGFR-mutant NSCLC (second indication). biospace.com
  6. Sacituzumab tirumotecan earns approval in China in pretreated advanced TNBC. OncLive, 27 November 2024. onclive.com
  7. Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS). Lancet Oncol 2018;19:1437-1448. doi
  8. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ATTRACTION-2). Lancet 2017;390:2461-2471. doi
  9. Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer (DESTINY-Gastric01). N Engl J Med 2020;382:2419-2430. doi

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Third-Line Gastric Cancer: TROP2-Directed Sac-TMT Met Its Overall Survival Goal in the TroFuse-015 Trial

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy